# Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma

> **NCT00403637** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 45 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** indacaterol maleate

## Key facts

- **NCT ID:** NCT00403637
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403637, "Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00403637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*